1. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.

2. Carlos W.G., Dela Cruz C.S., Cao B., et al. Novel Wuhan (2019-nCoV) Coronavirus. Am. J. Respir. Crit. Care. Med. 2020; 201: P7-P8.

3. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019 – nCoV) [online]. (2020). Available: https:// www.who.int/news-room/detail/30-01-2020-statementon-the-second-meeting-of-theinternational-health-regulations-(2005)-emergency-committee-regarding-theoutbreak-of-novelcoronavirus-(2019-ncov)а

4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/ naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it 2 5. https://covid19-2020.info/

5. Gaythorpe K., Imai N., Cuomo-Dannenburg G., et al. With support from other volunteers from the MRC Centre. et al. Symptom progression of COVID-19. Imperial College London (11-03-2020). doi: https://doi.org/10.25561/77344

6. Lai C.C., Liu Y.H., Wang C.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 2020. doi: 10.1016/j.jmii.2020.02.012

7. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003

8. Arentz M.Y., Klaff L., Lokhandwala S., et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; doi: 10.1001/jama.2020.4326

9. Yang X., Yu Y., Xu J., Shu H., et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; doi: 10.1016/S2213-2600(20)30079-5

10. Liu K., Fang Y.Y., Deng Y., et al.. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl). 2020; 133: 1025–1031.

11. Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020, doi: 10.1001/jama.2020.1585.

12. Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. doi: 10.1111/all.14238.

13. Mo P., Xing Y., Xiao Y., et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. 2020. doi: 10.1093/cid/ciaa270

14. Guo T., Fan Y., Chen M., et al.Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1017

15. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. doi: 10.1016/S0140-6736(20)30566-3

16. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.

17. Wang L., He W., Yu X., et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Infection. 2020. https://doi.org/10.1016/j.jinf.2020.03.019

18. Shi S., Qin M., Shen B., et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020, doi: 10.1001/jamacardio.2020.0950

19. Lian J., Jin X., Hao S., et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of Wuhan. Clin. Infect. Dis. 2020; pii: ciaa242. https://doi.org/10.1093/cid/ciaa242

20. Guan W.J.N.Z., Hu Y., Liang W.H., et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2002032

21. Guan W., Ph D., Liang W., et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J. 2020. https://doi.org/10.1183/13993003.00547-2020

22. Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2006923

23. Mehra M.R., Desai S.S., Kuy S., Henry T.D. and Patel A.N. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2007621

24. Reynolds H.R., Adhikari S., Pulgarin C., et al. ReninAngiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N. Engl. J. Med. 2020. doi: 10.1056/ NEJMoa2008975

25. Du R.-H., Liang L.-R., Yang C.-Q. et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur. Res. 2020; 55 (4). doi: 10.1183/13993003.00524-2020 11

26. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020 https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf

27. Yingzhen Du, Lei Tu, Pingjun Zhu, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study AJRCCM Articles in Press. Published April 03, 2020 as 10.1164/rccm.202003-0543OC Copyright © 2020 by the American. www.atsjournals.org/doi/pdf/10.1164/rccm.202003-0543OC

28. Chen T. Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br Med J. 2020;1091(March): m1091.https://doi.org/oi.org/doi:10.1136/bmj.m1091 Li B

29. Yang J., Zhao F.L. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020; (0123456789). https://doi.org/10.1007/s00392-020-01626-9

30. Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis. Int. J. Infect. Dis. 2020 Mar 12. pii: S1201- 9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017

31. Inciardi R.M.A.M., Lupi L., Cani D.S., et al. Characteristics and outcomes of patients hospitalized for COVID19 and cardiac disease in Northern Italy. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa388

32. Wei J.F., Huang F.Y., Xiong T.Y. et al. Acute myocardial injury is common in patients with covid-19 and impairs their prognosis. Heart. 2020. doi: 10.1136/heartjnl-2020-317007

33. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; 5: 1–3. doi: 10.1007/s00059-020-04909-z. 4

34. Arentz M., Yim E., Klaff L. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020; 323 (16): 1612– 1614. doi: 10.1001/jama.2020.4326. 6

35. Hui H., Zhang Y., Yang X. et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. 2020: 2020.02.24.20027052. 8

36. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8: 420–422.

37. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.

38. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T., Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020, doi: 10.1161/CIRCULATIONAHA.120.047349

39. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020, doi: 10.1001/jamainternmed.2020.0994

40. Liu J., Li S., Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv. 2020 2020.02.16.20023671

41. Guan W. J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. doi: 10.1101/2020.02.06.20020974

42. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease (COVID-19): Evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020. [Epub ahead of print]. doi: 101016/j.pcad.2020.03.001

43. Yingzhen Du, Lei Tu, Pingjun Zhu, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study AJRCCM Articles in Press. Published April 03, 2020 as 10.1164/rccm.202003-0543OC.

44. Zhou F., Yu T., Du R. et al. Clinical course and risk factorsfor mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.

45. Zheng Y.Y., Ma Y., Zhang J., et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020, doi: 101038/s41569-020-0360-5

46. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. March 5, 2020; doi: 101016/j.cell.2020.02.052. [epub ahead of print]

47. Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012; 2012: 256294-256294. doi: 101155/2012/256294

48. Zhang H., Penninger J.M., Li Y., et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. March 3, 2020; doi: 101007/s00134-020-05985-9

49. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I. Gallagher P.E. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605–2610.

50. Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R. Canver C.C. Increased angiotensin- (1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensinconverting enzyme Homologue ACE2. Circulation. 2003; 108: 1707–1712.

51. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B. Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43: 970–976.

52. Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., Sen S. Detection of soluble angiotensinconverting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008; 52: 750–754.

53. Ohtsuki M., Morimoto S.I., Izawa H., Ismail T.F., Ishibashi-Ueda H., Kato Y., Horii T., Isomura T., Suma H., Nomura M., Hishida H., Kurahashi H. and Ozaki Y. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int. J. Cardiol. 2010; 145: 333–334.

54. Sama I.E.R.A., Santema B.T., van Goor H., ter Maaten J.M., Cleland J.G.F., Rienstra M., Friedrich A.W., Samani N.J., Ng L.L., Dickstein K., Lang C.C., Filippatos G., Anker S.D., Ponikowski P., Metra M., van Veldhuisen D.J., Voors A.A. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa373

55. Guo J., Huang Z., Lin L. Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Am. Heart Assoc. 2020; 9: e016219.

56. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M.A., Fukamizu A., Hui C.C., Hein L., Uhlig S., Slutsky A.S., Jiang C. Penninger J.M. Angiotensinconverting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112–116.

57. Raiden S., Nahmod K., Nahmod V., Semeniuk G., Pereira Y., Alvarez C., Giordano M. Geffner J.R. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J. Pharmacol. Exp. Ther. 2002; 303: 45–51.

58. Hui D.S.C., Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019; 33 (4): 869–889. doi: 10.1016/j.idc.2019.07.001

59. Azhar E.I., Hui D.S.C., Memish Z.A., et al. The Middle East respiratory syndrome (MERS). Infect Dis. Clin. North Am. 2019; 33 (4): 891–905. doi: 101016/j.idc.2019.08.001

60. Li G., Fan Y., Lai Y., et al. Coronavirus infections and immune responses. Med. Virol. 2020; 92 (4): 424– 32. doi: 101002/jmv.25685

61. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017; 39 (5): 529–539. doi:101007/s00281-017-0629-x

62. Tang N., Li D., Wang X., et al. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020. doi: 101H11/jth14768

63. Klok F.A., Kuip M., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi: 10.1016/j.thromres.2020.04.013

64. Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.